In this era of precision medicine, rapid and efficient means of testing and predicting responses to therapy are urgently needed. Although platforms focusing on tumor cell intrinsic contributions to response to therapy are valuable, platforms that also take into account the microenvironment are particularly important. The microenvironment, including immune and stromal cells, and different kinds of signaling molecules, plays a key role in influencing cancer progression and response to therapy. In a new report, Bayin et al. offer a tumor explant model as a relatively simple, fast, and low-cost model to personalize treatment of transforming growth factor-β (TGF-β) inhibition for patients with high-grade glioma (HGG) [@bb0005].

The TGF-β pathway is a key regulator of cell growth, proliferation, differentiation, and apoptosis in normal development and neoplastic progression. TGF-β binds to the type II receptor (TGFBR2), which then recruits and activates the type I receptor (TGFBR1). Active TGFBR1 can initiate a signaling cascade through phosphorylating SMAD proteins or can signal through noncanonical pathways.

In HGG, TGF-β is frequently upregulated and correlates with worse patient survival [@bb0010]. TGF-β can act on both the tumor cells and microenvironment to promote proliferation and resistance to radiation, in addition to promoting angiogenesis and suppressing antitumor immune cell infiltration [@bb0015]. TGF-β is secreted by glioma stem cells to regulate their self-renewal, and TGF-β inhibition improves the radiation response and reduces survival of glioma stem cells [@bb0020], [@bb0025], [@bb0030], [@bb0035]. Targeting TGF-β signaling, therefore, is a valuable therapeutic strategy and is currently under investigation in several clinical trials [@bb0040], [@bb0045], [@bb0050], [@bb0055]. Because of intra- and intertumoral heterogeneity in HGG, strategies that define the subset of patients with HGG who would derive greatest benefit from TGF-β inhibition are needed.

In this report, Bayin et al. develop a tumor explant model as a relatively simple and low-cost model to test the response of TGF-β inhibition for patients with HGG. Fresh surgical specimens were diced and cultured on laminin-coated filters in the upper chamber of Transwell inserts and maintained in serum-free media. Notably, all seven tumors that were explanted were viable, demonstrating the ease in establishing this system.

Furthermore, the explants preserved tumor architecture and signaling for at least 1 week, sufficiently long to test response to the combination of TGF-β inhibition and radiotherapy *in situ*. The authors validated that TGF-β signaling was intrinsically active in all of the explants but with variable strength. Nuclear pSmad2 increased after stimulation with TGF-β and was reduced by the TGFβRI inhibitor LY364947 (RIKI). RIKI also decreased radiation-induced γ-H2AX foci formation and reduced Sox2 expression, suggesting that DNA damage repair and, potentially, stem cell properties were dependent on TGF-β signaling.

Interestingly and importantly, the explanted tumors showed distinct responses to TGF-β inhibition and irradiation. Five of the seven explanted tumors showed reduced γ-H2AX foci formation and suppression of radiation-induced Sox2 upregulation after RIKI treatment. One explant that was not responsive to RIKI showed no significant change in γ-H2AX foci after irradiation but did show reduced Sox2 upregulation. Another explant showed no difference in γ-H2AX or Sox2. A third explant showed reduced γ-H2AX but not Sox2. These disparate responses to irradiation in the setting of TGF-β inhibition appeared to be independent of molecular subtype and initial pSMAD2 levels and highlight the utility of the explant model in predicting response to TGF-β treatment. The model could easily be expanded to test interactions between combinations of inhibitors and radiation with a relatively quick readout and serve as a valuable tool to help guide therapy for patients in a timely manner.
